Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-27
DOI
10.1111/dom.15327
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
- (2023) Janet B. McGill et al. DIABETES OBESITY & METABOLISM
- Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes
- (2023) Pantelis Sarafidis et al. Clinical Journal of the American Society of Nephrology
- The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study
- (2023) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
- (2022) Ralph A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
- (2022) Jennifer B Green et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
- (2022) Ian H. de Boer et al. DIABETES CARE
- Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence
- (2022) Peter Rossing et al. KIDNEY INTERNATIONAL
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- 6. Glycemic Targets: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
- (2022) Rajiv Agarwal et al. JOURNAL OF HYPERTENSION
- Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences
- (2021) Sara Panizo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes
- (2021) Jaejin An et al. BMJ Open Diabetes Research & Care
- The mineralocorticoid receptor—an emerging player in metabolic syndrome?
- (2021) Moe Thuzar et al. JOURNAL OF HUMAN HYPERTENSION
- Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
- (2021) Alfred K. Cheung et al. KIDNEY INTERNATIONAL
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Real-World Diagnosis and Treatment of Diabetic Kidney Disease
- (2021) Fatima Rodriguez et al. ADVANCES IN THERAPY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Cardiac Mineralocorticoid Receptor (MR): A Therapeutic Target Against Ventricular Arrhythmias
- (2021) Michel F. Rossier Frontiers in Endocrinology
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
- (2021) Nina Vodošek Hojs et al. Pharmaceuticals
- Approaches towards tissue‐selective pharmacology of the mineralocorticoid receptor
- (2021) Dorien Clarisse et al. BRITISH JOURNAL OF PHARMACOLOGY
- Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
- (2021) Ajay Chaudhuri et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
- (2021) Jonatan Barrera-Chimal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
- (2021) Jonatan Barrera-Chimal et al. Nature Reviews Nephrology
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK
- (2021) Antonio González-Pérez et al. BMJ Open Diabetes Research & Care
- Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)
- (2020) Mizuki Takahashi et al. FEBS LETTERS
- Mineralocorticoid Receptors
- (2020) Achim Lother CIRCULATION RESEARCH
- Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association
- (2020) Janani Rangaswami et al. CIRCULATION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study
- (2020) Csaba P Kovesdy et al. Clinical Kidney Journal
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
- (2019) Andrew Whittaker et al. CTS-Clinical and Translational Science
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
- (2018) Michael Gerisch et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Cardiovascular Disease Consequences of CKD
- (2016) Alan S. Go SEMINARS IN NEPHROLOGY
- Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
- (2016) Makiko Yamada et al. XENOBIOTICA
- Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors
- (2015) Lucia Cea Soriano et al. Cardiovascular Diabetology
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2015) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
- A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
- (2011) Hari K Parthasarathy et al. JOURNAL OF HYPERTENSION
- Central regulation of blood pressure by the mineralocorticoid receptor
- (2011) Elise P. Gomez-Sanchez et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure
- (2010) Masayuki Yamaji et al. AMERICAN HEART JOURNAL
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
- (2009) U. F. Mehdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More